Navigation Links
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
Date:6/2/2009

ission among the overall randomized population (N=508), including individuals who did not enter the study extension and were assumed to be non-responders to therapy or not in steroid-free remission at week 50, was 46 percent of patients receiving REMICADE and azathioprine combination therapy, and 35 percent of patients receiving REMICADE monotherapy, compared with 24 percent of patients receiving azathioprine alone (P < 0.001 REMICADE with azathioprine vs. azathioprine monotherapy; P = 0.028 REMICADE monotherapy vs. azathioprine monotherapy; P = 0.035 REMICADE with azathioprine vs. REMICADE monotherapy). In an analysis of only those individuals participating in the extension (N=280), 72 percent of patients receiving REMICADE and azathioprine combination therapy, 61 percent of patients receiving REMICADE monotherapy and 55 percent receiving azathioprine alone achieved steroid-free remission at week 50 (P = 0.010 REMICADE and azathioprine vs. azathioprine monotherapy; P = 0.324 REMICADE monotherapy vs. azathioprine monotherapy; P = 0.065 REMICADE and azathioprine vs. REMICADE monotherapy).

A final safety evaluation for those patients who entered the extension study occurred at week 54. The proportion of patients with 1 or more serious adverse events during the study was 27 percent (n=43) in the AZA monotherapy treatment group, 24 percent (n=39) in the REMICADE monotherapy treatment group, and 15 percent (n=27) in the combined REMICADE and AZA treatment group. No new serious adverse events, such as opportunistic infections, malignancies or death, were reported between weeks 30 and 54.

Dr. William J. Sandborn, Inflammatory Bowel Disease Clinic, Mayo Clinic, and principal investigator for the SONIC trial, will present the results of the SONIC extension trial on Tuesday, June 2 at 3:30 PM at the annual Digestive Disease Week meeting.

In 1998, REMICADE became the first anti-T
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 XRpro Sciences, Inc., a ... and development services which features high throughput transporter ... announced financial results for the year ended December ... Chairman of XRpro Sciences commented, "We have completed ... development stage to commercial stage in large part ...
(Date:3/27/2015)... LAVAL, Quebec , March 27, 2015  Valeant ... announced today the closing of its previously announced registered ... States (the "Offering"). Pursuant to the Offering, ... of $199.00 per share, for aggregate gross proceeds of ... filed with the U.S. Securities and Exchange Commission a ...
(Date:3/27/2015)... Calif. , March 27, 2015 The ... life of myeloma patients while working toward prevention and ... (D-NY) for introducing a federal resolution (H. Res. ... March 2015 as "National Multiple Myeloma Awareness Month." ... with myeloma worldwide, and more than 110,000 new cases ...
Breaking Medicine Technology:XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2
... SIRO Clinpharm, a global Contract Research Organization (CRO) with ... alliance with Mediscis, an early drug development company based in ... an established expert in GCP compliant early phase drug development ... all study phases for the pharmaceutical and biotech industry. ...
... 17 It is the bane of many women,s existence: fat ... commonly referred to as "bra bulge." Making matters even worse: bra ... of the body, making women go to great lengths to camouflage ... too big, or body-slimming outfits that temporarily slims them down. ...
Cached Medicine Technology:SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise 2A New Weapon In The Battle Of The Bra Bulge 2
(Date:3/29/2015)... (PRWEB) March 29, 2015 Final ... new transition from Pixel Film Studios, entitled TranSports. ... made exclusively for Final Cut Pro X,” said Christiana ... users the tools needed to effortlessly transition using this ... TranSports, a new and uniquely styled transition pack for ...
(Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared ... UniWigs during the Easter Holidays from today until April ... April Fools’ Day. , As the winter fades and ... Easter Festival, with religious origins to countries in Europe ... Christmas. The best wig provider, UniWigs, would like to ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Pitching speed, player’s ... history of shoulder and elbow injuries, according to new research ... ( AOSSM ) Specialty Day. , “Our findings indicate that ... 20% increase in likelihood of a history of injury, a ... a 12% increase likelihood of a history of injury, and ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the ... the first time, key information for understanding and treating ... newly posted story on the Surviving Mesothelioma website. ... Columbia, the British Columbia Cancer Agency, and PhenoPath lab ... molecular alterations and mutations that can lead to ...
Breaking Medicine News(10 mins):Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... 18 Unitrin Direct, an,auto insurance company that ... of affordable coverage with outstanding personal,service, has implemented ... (VHT) that is dramatically reducing the time customers ... customers don,t have to hold if a Unitrin ...
... issue of the Journal of Periodontology (JOP) found that smokers ... than non-smokers. , The study followed 10 smokers and 10 ... smoke on the long term outcomes of a treatment to ... teeth. After two years, residual gum recession around the ...
... bouncers, the bodyguards, the ,shotgun, riders, the overseers, the matre ... the patient ... Often we are the only thing between ... us.", Welcome to the nurse,s world, through the words of ... appears in a paper published in the current issue of ...
... life improve with frequent dialysis, , , TUESDAY, Sept. ... most nights of the week may be better ... dialysis, new research suggests. , In a six-month ... dialysis therapy, researchers found that heart health, blood ...
... in vendor, provider and consulting sector to ... 18 Health Level Seven (HL7), a,preeminent healthcare ... announced the appointment of John Quinn,as Chief Technology ... in principle and Quinn, who is CTO of ...
... Available for All Three Major MR ... Scanner Manufacturers, ... 3.0T Prostate eCoil (TM) MR Endorectal Coil compatible,with magnetic resonance (MR) ... for GE scanners in 2006. (Logo: http://www.newscom.com/cgi-bin/prnh/20040309/MEDRADLOGO ) ...
Cached Medicine News:Health News:New Technology at Unitrin Direct Gives Customers an Alternative to Waiting 2Health News:New Technology at Unitrin Direct Gives Customers an Alternative to Waiting 3Health News:Nurses describe dedication, frustration associated with their jobs 2Health News:Nurses describe dedication, frustration associated with their jobs 3Health News:Nighttime Home Dialysis a Boon for Kidney Patients 2Health News:Nighttime Home Dialysis a Boon for Kidney Patients 3Health News:Health Level Seven Appoints John Quinn as CTO 2Health News:Health Level Seven Appoints John Quinn as CTO 3Health News:MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners 2Health News:MEDRAD Announces eCoil(TM) for Siemens, Philips 3.0T MR Scanners 3
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
... The S8 Elite is the premium CPAP device ... generators. The S8 line of flow generators are ... first flow generators to include an option of ... to the device for simplicity and convenience. Premium ...
Medicine Products: